PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of aacPermissionsJournals.ASM.orgJournalAAC ArticleJournal InfoAuthorsReviewers
 
Antimicrob Agents Chemother. 1997 May; 41(5): 1099–1107.
PMCID: PMC163857

Unique intracellular activation of the potent anti-human immunodeficiency virus agent 1592U89.

Abstract

The anabolism of 1592U89, (-)-(1S,4R)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclo pentene-1-methanol, a selective inhibitor of human immunodeficiency virus (HIV), was characterized in human T-lymphoblastoid CD4+ CEM cells. 1592U89 was ultimately anabolized to the triphosphate (TP) of the guanine analog (-)-carbovir (CBV), a potent inhibitor of HIV reverse transcriptase. However, less than 2% of intracellular 1592U89 was converted to CBV, an amount insufficient to account for the CBV-TP levels observed. 1592U89 was anabolized to its 5'-monophosphate (MP) by the recently characterized enzyme adenosine phosphotransferase, but neither its diphosphate (DP) nor its TP was detected. The MP, DP, and TP of CBV were found in cells incubated with either 1592U89 or CBV, with CBV-TP being the major phosphorylated species. We confirmed that CBV is phosphorylated by 5'-nucleotidase and that mycophenolic acid increased the formation of CBV-TP from CBV 75-fold. However, mycophenolic acid did not stimulate 1592U89 anabolism to CBV-TP. The adenosine deaminase inhibitor erythro-9-(2-hydroxy-3-nonyl)adenine (EHNA) did not inhibit CBV-TP formation from CBV or 1592U89, whereas the adenylate deaminase inhibitor 2'-deoxycoformycin selectively inhibited 1592U89 anabolism to CBV-TP and reversed the antiviral activity of 1592U89. 1592U89-MP was not a substrate for adenylate deaminase but was a substrate for a distinct cytosolic deaminase that was inhibited by 2'-deoxycoformycin-5'-MP. Thus, 1592U89 is phosphorylated by adenosine phosphotransferase to 1592U89-MP, which is converted by a novel cytosolic enzyme to CBV-MP. CBV-MP is then further phosphorylated to CBV-TP by cellular kinases. This unique activation pathway enables 1592U89 to overcome the pharmacokinetic and toxicological deficiencies of CBV while maintaining potent and selective anti-HIV activity.

Full Text

The Full Text of this article is available as a PDF (314K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Agarwal RP. Inhibitors of adenosine deaminase. Pharmacol Ther. 1982;17(3):399–429. [PubMed]
  • Allison AC, Kowalski WJ, Muller CD, Eugui EM. Mechanisms of action of mycophenolic acid. Ann N Y Acad Sci. 1993 Nov 30;696:63–87. [PubMed]
  • Balzarini J. Metabolism and mechanism of antiretroviral action of purine and pyrimidine derivatives. Pharm World Sci. 1994 Apr 15;16(2):113–126. [PubMed]
  • Bondoc LL, Jr, Shannon WM, Secrist JA, 3rd, Vince R, Fridland A. Metabolism of the carbocyclic nucleoside analogue carbovir, an inhibitor of human immunodeficiency virus, in human lymphoid cells. Biochemistry. 1990 Oct 23;29(42):9839–9843. [PubMed]
  • Bondoc LL, Jr, Robbins BL, Ahluwalia GS, Mitsuya H, Johns DG, Fridland A. Modulation of metabolism and anti-HIV-1 activity of purine 2',3'-dideoxynucleosides by IMP dehydrogenase inhibitors. Adv Exp Med Biol. 1991;309A:49–53. [PubMed]
  • Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976 May 7;72:248–254. [PubMed]
  • Brouwer KR, St Claire RL, Lagarde J, Patanella JE, Walsh JS, Miwa GT. The pharmacokinetics of (-)-carbovir in rats. Evidence for nonlinear elimination. Drug Metab Dispos. 1990 Nov-Dec;18(6):1078–1083. [PubMed]
  • Daluge SM, Good SS, Faletto MB, Miller WH, St Clair MH, Boone LR, Tisdale M, Parry NR, Reardon JE, Dornsife RE, et al. 1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity. Antimicrob Agents Chemother. 1997 May;41(5):1082–1093. [PMC free article] [PubMed]
  • Daluge SM, Purifoy DJ, Savina PM, St Clair MH, Parry NR, Dev IK, Novak P, Ayers KM, Reardon JE, Roberts GB, et al. 5-Chloro-2',3'-dideoxy-3'-fluorouridine (935U83), a selective anti-human immunodeficiency virus agent with an improved metabolic and toxicological profile. Antimicrob Agents Chemother. 1994 Jul;38(7):1590–1603. [PMC free article] [PubMed]
  • De Clercq E. HIV inhibitors targeted at the reverse transcriptase. AIDS Res Hum Retroviruses. 1992 Feb;8(2):119–134. [PubMed]
  • Dornsife RE, St Clair MH, Huang AT, Panella TJ, Koszalka GW, Burns CL, Averett DR. Anti-human immunodeficiency virus synergism by zidovudine (3'-azidothymidine) and didanosine (dideoxyinosine) contrasts with their additive inhibition of normal human marrow progenitor cells. Antimicrob Agents Chemother. 1991 Feb;35(2):322–328. [PMC free article] [PubMed]
  • Fleischer S, Kervina M. Subcellular fractionation of rat liver. Methods Enzymol. 1974;31:6–41. [PubMed]
  • Frieden C, Gilbert HR, Miller WH, Miller RL. Adenylate deaminase: potent inhibition by 2'-deoxycoformycin 5'-phosphate. Biochem Biophys Res Commun. 1979 Nov 14;91(1):278–283. [PubMed]
  • Frieden C, Kurz LC, Gilbert HR. Adenosine deaminase and adenylate deaminase: comparative kinetic studies with transition state and ground state analogue inhibitors. Biochemistry. 1980 Nov 11;19(23):5303–5309. [PubMed]
  • Furman PA, Fyfe JA, St Clair MH, Weinhold K, Rideout JL, Freeman GA, Lehrman SN, Bolognesi DP, Broder S, Mitsuya H, et al. Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase. Proc Natl Acad Sci U S A. 1986 Nov;83(21):8333–8337. [PubMed]
  • Furman PA, Barry DW. Spectrum of antiviral activity and mechanism of action of zidovudine. An overview. Am J Med. 1988 Aug 29;85(2A):176–181. [PubMed]
  • Furman PA, Davis M, Liotta DC, Paff M, Frick LW, Nelson DJ, Dornsife RE, Wurster JA, Wilson LJ, Fyfe JA, et al. The anti-hepatitis B virus activities, cytotoxicities, and anabolic profiles of the (-) and (+) enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine. Antimicrob Agents Chemother. 1992 Dec;36(12):2686–2692. [PMC free article] [PubMed]
  • Garvey EP, Krenitsky TA. A novel human phosphotransferase highly specific for adenosine. Arch Biochem Biophys. 1992 Jul;296(1):161–169. [PubMed]
  • Hao Z, Cooney DA, Hartman NR, Perno CF, Fridland A, DeVico AL, Sarngadharan MG, Broder S, Johns DG. Factors determining the activity of 2',3'-dideoxynucleosides in suppressing human immunodeficiency virus in vitro. Mol Pharmacol. 1988 Oct;34(4):431–435. [PubMed]
  • Hartman NR, Ahluwalia GS, Cooney DA, Mitsuya H, Kageyama S, Fridland A, Broder S, Johns DG. Inhibitors of IMP dehydrogenase stimulate the phosphorylation of the anti-human immunodeficiency virus nucleosides 2',3'-dideoxyadenosine and 2',3'-dideoxyinosine. Mol Pharmacol. 1991 Jul;40(1):118–124. [PubMed]
  • Huang SH, Remmel RP, Zimmerman CL. The bioavailability and nonlinear clearance of (-)-carbovir in the rat. Pharm Res. 1991 Jun;8(6):739–743. [PubMed]
  • Johnson MA, Fridland A. Phosphorylation of 2',3'-dideoxyinosine by cytosolic 5'-nucleotidase of human lymphoid cells. Mol Pharmacol. 1989 Aug;36(2):291–295. [PubMed]
  • Lowe DM, Alderton WK, Ellis MR, Parmar V, Miller WH, Roberts GB, Fyfe JA, Gaillard R, Ertl P, Snowden W, et al. Mode of action of (R)-9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine against herpesviruses. Antimicrob Agents Chemother. 1995 Aug;39(8):1802–1808. [PMC free article] [PubMed]
  • Mahony WB, Domin BA, Daluge SM, Miller WH, Zimmerman TP. Enantiomeric selectivity of carbovir transport. J Biol Chem. 1992 Oct 5;267(28):19792–19797. [PubMed]
  • Miller RL, Adamczyk DL, Miller WH. Adenosine kinase from rabbit liver. I. Purification by affinity chromatography and properties. J Biol Chem. 1979 Apr 10;254(7):2339–2345. [PubMed]
  • Miller WH, Daluge SM, Garvey EP, Hopkins S, Reardon JE, Boyd FL, Miller RL. Phosphorylation of carbovir enantiomers by cellular enzymes determines the stereoselectivity of antiviral activity. J Biol Chem. 1992 Oct 15;267(29):21220–21224. [PubMed]
  • Mitsuya H, Yarchoan R, Kageyama S, Broder S. Targeted therapy of human immunodeficiency virus-related disease. FASEB J. 1991 Jul;5(10):2369–2381. [PubMed]
  • Orr DC, Figueiredo HT, Mo CL, Penn CR, Cameron JM. DNA chain termination activity and inhibition of human immunodeficiency virus reverse transcriptase by carbocyclic 2',3'-didehydro-2',3'-dideoxyguanosine triphosphate. J Biol Chem. 1992 Feb 25;267(6):4177–4182. [PubMed]
  • Parker WB, White EL, Shaddix SC, Ross LJ, Buckheit RW, Jr, Germany JM, Secrist JA, 3rd, Vince R, Shannon WM. Mechanism of inhibition of human immunodeficiency virus type 1 reverse transcriptase and human DNA polymerases alpha, beta, and gamma by the 5'-triphosphates of carbovir, 3'-azido-3'-deoxythymidine, 2',3'-dideoxyguanosine and 3'-deoxythymidine. A novel RNA template for the evaluation of antiretroviral drugs. J Biol Chem. 1991 Jan 25;266(3):1754–1762. [PubMed]
  • Parker WB, Shaddix SC, Bowdon BJ, Rose LM, Vince R, Shannon WM, Bennett LL., Jr Metabolism of carbovir, a potent inhibitor of human immunodeficiency virus type 1, and its effects on cellular metabolism. Antimicrob Agents Chemother. 1993 May;37(5):1004–1009. [PMC free article] [PubMed]
  • Rundell KW, Tullson PC, Terjung RL. Altered kinetics of AMP deaminase by myosin binding. Am J Physiol. 1992 Aug;263(2 Pt 1):C294–C299. [PubMed]
  • Siaw MF, Coleman MS. In vitro metabolism of deoxycoformycin in human T lymphoblastoid cells. Phosphorylation of deoxycoformycin and incorporation into cellular DNA. J Biol Chem. 1984 Aug 10;259(15):9426–9433. [PubMed]
  • Spector T, Jones TE, Beacham LM., 3rd Conversion of 2,6-diamino-9-(2-hydroxyethoxymethyl)purine to acyclovir as catalyzed by adenosine deaminase. Biochem Pharmacol. 1983 Sep 1;32(17):2505–2509. [PubMed]
  • Tisdale M, Alnadaf T, Cousens D. Combination of mutations in human immunodeficiency virus type 1 reverse transcriptase required for resistance to the carbocyclic nucleoside 1592U89. Antimicrob Agents Chemother. 1997 May;41(5):1094–1098. [PMC free article] [PubMed]
  • Tuttle JV, Krenitsky TA. Effects of acyclovir and its metabolites on purine nucleoside phosphorylase. J Biol Chem. 1984 Apr 10;259(7):4065–4069. [PubMed]
  • Venner PM, Glazer RI. The metabolism of 2'-deoxycoformycin by L1210 cells in vitro. Biochem Pharmacol. 1979 Nov 1;28(21):3239–3242. [PubMed]
  • Vince R, Hua M, Brownell J, Daluge S, Lee FC, Shannon WM, Lavelle GC, Qualls J, Weislow OS, Kiser R, et al. Potent and selective activity of a new carbocyclic nucleoside analog (carbovir: NSC 614846) against human immunodeficiency virus in vitro. Biochem Biophys Res Commun. 1988 Oct 31;156(2):1046–1053. [PubMed]
  • Vince R, Brownell J. Resolution of racemic carbovir and selective inhibition of human immunodeficiency virus by the (-) enantiomer. Biochem Biophys Res Commun. 1990 May 16;168(3):912–916. [PubMed]
  • White EL, Parker WB, Macy LJ, Shaddix SC, McCaleb G, Secrist JA, 3rd, Vince R, Shannon WM. Comparison of the effect of Carbovir, AZT, and dideoxynucleoside triphosphates on the activity of human immunodeficiency virus reverse transcriptase and selected human polymerases. Biochem Biophys Res Commun. 1989 Jun 15;161(2):393–398. [PubMed]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)